Carisbamate
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
In adult rats, the administration of lithium–pilocarpine (LiPilo) reproduces most clinical and neuropathological features of…
As reported previously, in the lithium–pilocarpine model of temporal lobe epilepsy (TLE), carisbamate (CRS) produces strong…
Alcoholism is a complex heterogeneous disease and a number of neurotransmitter and neuromodulator systems have been implicated in…
Purpose: To assess the efficacy, safety, and tolerability of adjunctive carisbamate treatment at 800 mg/day and 1,200 mg/day in…
Background and purpose: Carisbamate is being developed for adjuvant treatment of partial onset epilepsy. Carisbamate produces…
Objective.— This study explored the dose‐response relationship of carisbamate administered at doses of 100 mg per day, 300 mg per…
BACKGROUND
Since 1994, when naltrexone (Revia) was approved by the FDA for the treatment of alcoholism, only 2 other drugs…
Purpose: Animal models with spontaneous epileptic seizures may be useful in the discovery of new antiepileptic drugs (AEDs). The…